SITC 2023 | Planned 2024 studies in anti-PD-1 resistance

Brent A. Hanks, MD, PhD, Duke University School of Medicine, Durham, NC, outlines strategies to overcome tumor-driven PD-1 immunotherapy resistance. In order to better understand the nature of the genetic reprogramming mechanisms, clinical biomarker studies are necessary in patients with other cancer types. There is extensive data with significant positive predictive values (PPV) for resistance in melanoma but little data on other cancers. Analysis of this data is important so that starting resistant patients on expensive therapies can be avoided. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.